Boyapati A, Schwartzman S, Msihid J, et al. - Researchers undertook this post hoc analysis to determine if baseline interleukin‐6 (IL‐6) levels could be used as a predictor of sarilumab treatment responses in rheumatoid arthritis (RA) cases in two phase III studies. In RA patients, measurements of serum IL‐6 levels were obtained before receiving sarilumab 200 mg (n = 148) or adalimumab 40 mg (n = 152) every two weeks (Q2W) (MONARCH) or sarilumab 150 or 200 mg+methotrexate (n = 401 and n = 396, respectively) or placebo+methotrexate (n = 397) Q2W (MOBILITY). Findings are suggestive of the likely role of IL‐6 as a prognostic marker of disease progression as well as severity. It was also inferred that sarilumab vs adalimumab or methotrexate may be beneficial for patients with high IL‐6.